DEVELOPING EUROPE & CIS
The main revenue contributor to our Developing Europe & CIS business is the Thrombosis Brands, followed by Regional Brands which are OTC and prescription.
The Czech Republic
- The Developing Europe & CIS Injectable thrombosis market was valued at EUR318 million as at March 2020.
Source: IQVIA – March 2020
Number of products launched:
Average staff turnover:
Number of product recalls:
Number of work-related fatalities:
|Number of permanent employees|
|Sterile Focus Brands||2 116||2 289||(8)|
|Thrombosis Brands||1 942||1 990||(2)|
|Total||2 551||2 682||(5)|
Note: Commercial Pharmaceuticals revenue by customer geography.